FDA Grants Extra Patent Time for Mystery Drug GRAFAPEX
Published Date: 12/10/2025
Notice
Summary
The FDA has set the official review period for the drug GRAFAPEX, which helps the company extend its patent protection. This means the drug maker could get more time to exclusively sell GRAFAPEX, potentially affecting competition and profits. People can challenge the dates or the company’s effort in the review process by early to mid-2026.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA sets GRAFAPEX review period
FDA determined the regulatory review period for the drug GRAFAPEX (treosulfan) is 9,906 days total: 8,281 days in the testing phase and 1,625 days in the approval phase. The key dates are: IND effective December 10, 1997; NDA submitted August 11, 2020; and approval on January 21, 2025. This determination establishes the maximum potential length of a patent extension and the applicant is seeking 5 years of patent term extension.
Public can challenge dates and diligence
Anyone with knowledge that the published dates are incorrect may ask FDA for a redetermination by February 9, 2026, and any interested person may petition FDA regarding whether the applicant acted with due diligence during the regulatory review period by June 8, 2026. Instructions for electronic and written submissions are provided in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
Previous / Next Documents
Previous: 2025-22381, Foreign-Trade Zone 40; Application for Subzone; Atlantic Veal & Lamb, LLC; Creston and Sterling, Ohio
Atlantic Veal & Lamb, LLC wants to join Foreign-Trade Zone 40 by adding two sites in Creston and Sterling, Ohio. This move could help the company save money on import taxes and speed up their business. Public comments are open until January 20, 2026, so folks have a chance to weigh in before the final decision.
Next: 2025-22383, Self-Regulatory Organizations; NYSE American LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change of Amendments to Rules 915 and 916
NYSE American is updating its rules to make it easier to list options on Commodity-Based Trust Shares, just like Nasdaq did earlier this year. This change affects traders and investors who deal with these options and kicks in right away with no extra fees. It’s a smart move to keep NYSE American competitive and ready for more trading action.